A Study Of Diagnostic And Monitoring Value Of Lysophosphatidic Acid For Human Epithelial Ovarian Cancer

Nowadays ovarian cancer has become the fifth most common cause of death from all cancers occurring in woman and leading cause of mortality from Gynecologic cancer . The human epithelial ovarian cancer constitutes approximately 90% of ovarian malignancies and thought to be the most malignant in different category ovarian cancer. The main cause of treatment failure and death for cancer patients is correlated with no symptom during early stages .70% of. women with epithelial ovarian cancer are diagnosed with advanced -stage disease, and survival at 5 years is poor 28%.Alternatively,in the 15%of women fortunate enough to have early disease detection and malignancy with in the ovary ,a 95%survival can be anticipated .Therefore it is very important for the epithelial ovarian cancer patients to explore the active diagnostic method in early stage .Lysophosphatidic acid (LPA:1-acyl-2-lyso-sn-3phos-phate) is one kind of intercellular phospholipid signaling molecule which recently discovered. It causes many kinds of biological effect through the G protein coupl- acceptor, which is called is the multi-purpose phospho-lip in messenger. In 1995 , Xu[2] and his colleagues firstly discovered that LPA was present in the ascitic fluid of patients with human epithelial ovarian cancer . After that, LPA has become the focal point of investigating the mechanism of genesis and development of human epithelial ovarian cancer. Many studies suggested that LPA was produced a small volume in normal ovarian. endothelial cells ,but a lot in epithelial ovarian cancer cells. The elevated LPA levels that created by the ovarian cancer cells. induced the high levels of ascitic fluid in the patients with tumor load .LPA. also prossesses a range of biological activites similar to growth factors .In 1998 , Xu. and his colleagues discovered the LPA levels in the plasma from patients with human epithelial ovarian cancer. was higher than the normal people and the patients with ovarian benign tumor, the LPA may be a biomarker for the diagnosis of human epithelial ovarian cancer . In the recent researches abroad, LPA has been shown to stimulate proliferation and invasion of ovarian cancer cells through different ways ,in addition LPA protects ovarian cancer cells against chemotherapeutic drug-induced apoptosis and it has close relationship with the human epithelial ovarian cancer. But, the using of LPA in the diagnosis and monitoring of human epithelial ovarian cancer .is still in advancing front. in our country.Objective: Through detecting the preoperative and postoperative LPA levels in the plasma , ascetic fluid LPA levels, abdominal cavity rinse solution LPA levels, to determine whether the elevated levels of LPA in plasma from patients with human epithelial ovarian cancer. compared with healthy controls and to evaluate whether an elevated LPA plasma level may be a biomarker for the diagnosis of early human epithelial ovarian cancer and monitoring of human epithelial ovarian cancer. At equal pace, to investigate whether the LPA levels in diagnosing early human epithelial ovarian cancer is more super than the CA-125. The experiment is a prospective , randomized, .controlled research.Methods1 Patients and Groups:Selecting 40 patients cases with the human epithelial ovarian cancer from the Fourth Hospital of Hebei Medical University who had ever been received surgery to treat, (average age 51,serous cystadenocarcinoma 19 cases, mucinous cystadenocarcinoma 9 cases ,endometrioid carcinoma 12 cases ) ;synchronization 20 patients cases with ovarian benign tumor (average age 47 ,serous cystadenoma 12 cases ,mucinous cystadenoma 8 cases).2 Methods: Using the plasma LPA measurement reagent methods which Beijing Twofish Science and Technology Development Limited Company provides to detect the preoperative and postoperative plasma LPA levels and ascetic fluid LPA levels of patients with human epithelial ovarian cancer .The same methods to detect the preoperative and postoperative plasma LPA levels and abdominal cavity rinse solution LPA levels of patients with ovarian benign tumor as controlled groups . At equal pace, detecting preoperative and postoperative blood serum CA125 levels of all patients.3 Statistical analysis: According to statistics data processing principle , all data should be checked by T-test; Kruskal-Wallis H-test ; rank-sum test(z),χ2 test(χ2),statistical analysis. It has statistics significance by P < 0.05.Results1 The median value of preoperative LPA levels in the plasma from patients with human epithelium ovarian cancer :there was 39 of 40 cases preoperative LPA levels in the plasma > 3.2mol/L, the average preoperative LPA levels in the plasma from human epithelium ovarian cancer preoperative is 5.89±1.98μmol/L。Contrasting with the normal plasma LPA levels of people 3.2mol/L, t=8.592, P <0.01, the distinction is prominent.2 The median value of preoperative LPA levels in the plasma from patients with human epithelium ovarian cancer and ovarian benign tumor : the average age of patients with human epithelium ovarian cancer is 51, and the average age of patients with benign tumor is 47, the distinction of the two age (t=0.498 P>0.05) is not prominent; the preoperative LPA levels in the plasma of patients with human epithelium ovarian cancer is 5.89±1.98mol/L while the LPA levels of patients with benign tumor patients is 1.65±0.71μmol/L. z=5.07 , P <0.01 ,the difference is prominent. 3 The median value of preoperative LPA levels in the plasma and CA125 levels from patients with stage I of human epithelium ovarian cancer:3 of 4 cases plasma LPA levels elevated in stage I of human epithelium ovarian cancer, while only 1 of 4 CA125 levels elevated in stage I human epithelium ovarian cancer. The group of ovarian cancer LPA level in the plasma and the CA125 level relevance comparison: the two has the relevance ,also presents positive correlation (coefficient correlation r= 0.736 ,P<0.01).4 The difference of preoperative LPA levels in the plasma is not prominent in different types, stages, and grades of human epithelium ovarian cancer, (P>0.05).5 The median value of preoperative and postoperative LPA levels in the plasma from patients with human epithelium ovarian patients: the preoperative LPA levels in the plasma is 5.89±1.98μmol/L while the postoperative LPA levels is 2.87±1.34μmol/L, the distinction is prominent (t=13.435 ,P<0.01).6 The LPA levels in the ascetic fluid from patients with the ovarian epithelium cancer and the LPA levels in the abdominal cavity rinse solution from patients with benign ovarian epithelium tumor: The LPA levels in the ascetic fluid is 5.68±1.75μmol/L, which is obviously higher than the LPA levels in the benign abdominal cavity rinse solution 1.34±0.77 mol/L, z=5.383,P<0.01 the difference is prominent. 7 The preoperative LPA levels in the plasma and the LPA levels in the ascetic fluid from patients with human ovarian epithelium cancer: 13of 20 cases LPA levels in the ascetic fluid higher than LPA levels in the plasma ,but the difference is not prominent, P>0.05.ConclusionThe LPA levels in the plasma from the patients with human epithelium ovarian cancer is higher than the normal level and the patients with ovarian benign tumor. we can believe that LPA is liable to be a new biomarker for detecting and monitoring the ovarian epithelium cancer. Determining LPA , we think, is superior to CA125 in early detecting human epithelium ovarian cancer , in addition LPA and CA125 presents positive correlation, they can diagnose the ovarian epithelium cancer in combination.